Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

NCT05468060 | Completed Phase 1

• 1 other identifier: PA1010-101
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetics characteristics of single ascending dose (SAD) of PA1010 tablets in Chinese healthy adults and the impact of food and gender on the pharmacokinetics

Conditions

Chronic HBV Infection

Outcome Measures

Primary Outcomes (15)

• Number of subjects having abnormal hematology laboratory parameters

  Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

  Up to 72 hours after last dose

• Number of subjects with abnormal clinical chemistry parameters

  Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

  Up to 72 hours after last dose

• Number of subjects with abnormal values for urinalysis

  Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

  Up to 72 hours after last dose

• Number of subjects with abnormal with blood coagulation function

  Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

  Up to 72 hours after last dose

• Ear temperature

  Vital sign-ear temperature

  Up to 72 hours after last dose

• Systolic and diastolic blood pressure

  Vital sign-Systolic and diastolic blood pressure

  Up to 72 hours after last dose

• Pulse rate

  Vital sign-Pulse rate

  Up to 72 hours after last dose

• Breathing rate

  Vital sign-Breathing rate

  Up to 72 hours after last dose

• ECG parameter-QTc interval

  A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically calculates the QTc intervals

  Up to 72 hours after last dose

• ECG parameter-PR interval

  A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures PR intervals

  Up to 72 hours after last dose

• ECG parameter-QRS duration

  A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures QRS duration

  Up to 72 hours after last dose

• Number of subjects experiencing adverse events (AEs)

  An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment.

  Up to 4days after the last dose

• Pharmacokinetics of single dose of PA1010-Cmax

  Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Maximum Observed Plasma Concentration (Cmax)

  Up to 72 hours after last dose

• Pharmacokinetics of single dose of PA1010-Tmax

  Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Time to Reach Maximum Observed Plasma Concentration (Tmax)

  Up to 72 hours after last dose

• Pharmacokinetics of single dose of PA1010-AUC

  Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Area Under the Plasma Concentration-Time Curve (AUC)

  Up to 72 hours after last dose

Secondary Outcomes (4)

• Pharmacokinetics of single dose of PA1010-T1/2

  Up to 72 hours after last dose

• Pharmacokinetics of single dose of PA1010-Vz/F

  Up to 72 hours after last dose

• Pharmacokinetics of single dose of PA1010-λz

  Up to 72 hours after last dose

• Pharmacokinetics of single dose of PA1010-CL/F

  Up to 72 hours after last dose

Study Arms (8)

PA1010 5mg

EXPERIMENTAL

Ten subjects will be randomly assigned in a ratio of 4:1 to receive 5 mg of PA1010 tablets or 5mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.

Drug: PA1010

PA1010 10mg

EXPERIMENTAL

Ten subjects will be randomly assigned in a ratio of 4:1 to receive 10mg of PA1010 tablets or 10mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.

Drug: PA1010

PA1010 20mg

EXPERIMENTAL

Ten subjects will be randomly assigned in a ratio of 4:1 to receive 20mg of PA1010 tablets or 20mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.

Drug: PA1010

PA1010 30mg

EXPERIMENTAL

Ten subjects will be randomly assigned in a ratio of 4:1 to receive 30mg of PA1010 tablets or 30mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.

Drug: PA1010

PA1010 45mg

EXPERIMENTAL

Ten subjects will be randomly assigned in a ratio of 4:1 to receive 45mg of PA1010 tablets or 45mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.

Drug: PA1010

PA1010 60mg

EXPERIMENTAL

Ten subjects will be randomly assigned in a ratio of 4:1 to receive 60mg of PA1010 tablets or 60mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.

Drug: PA1010

PA1010 10mg before and after meals

EXPERIMENTAL

Ten subjects will be administered 10mg PA1010 after overnight fasting for 10 hours in the first cycle, and then will be administered 10mg PA1010 within 30 minutes after high-fat meal in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.

Drug: PA1010

PA1010 10mg after and before meals

EXPERIMENTAL

Ten subjects will be administered 10mg PA1010 within 30 minutes after the high-fat meal in the first cycle, and then will be administered 10mg PA1010 after overnight fasting 10 hours in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.

Drug: PA1010

Interventions

PA1010 DRUG

Placebo as control

PA1010 10mg; PA1010 10mg after and before meals; PA1010 10mg before and after meals; PA1010 20mg; PA1010 30mg; PA1010 45mg; PA1010 5mg; PA1010 60mg

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female subjects aged between 18 and 55 (including upper and lower limits);
• Body mass index (BMI) is between 18 and 28 kg/m2 (including upper and lower limits);
• During the study period (from signing the informed consent to the last follow-up) and within 90 days after the last dose, there is no possibility of pregnancy (or making the sexual partner pregnant), childbirth or lactation, including:
• Menopausal women who have menopause for more than 12 months or undergo sterilization (such as hysterectomy or bilateral ovariectomy);
• Postmenopausal women, who have negative urine pregnancy test within 24 hours before the first dose, are willing to take more than one effective contraceptive method from the screening period to 90 days after the last dose, including intrauterine device, fallopian tube ligation, double barrier method (condom / vaginal diaphragm + spermicide) and male partner vas deferens ligation, but do not include oral contraceptives;
• Men are willing to take more than one effective contraceptive method from the first dose to 90 days after the last dose, including vasectomy, double barrier method, female partner's use of contraceptives, intrauterine device or tubal ligation, etc.;
• Avoid sex during the study period to 90 days after the last dose;
• There is no history of major diseases, and the physical examination, vital signs, electrocardiogram and laboratory examination results during the screening period are normal, or although they exceed the normal reference value range, they are judged by the researcher to be of no clinical significance;
• Be able to communicate with clinical staff normally and comply with the requirements of this study;
• Sign the informed consent form to indicate willingness to participate in this study.

You may not qualify if:

• Any medical condition that the investigator considers to be likely to increase the risk of study participation (in particular, a history of esophageal or gastrointestinal ulcers), that may interfere with drug absorption, distribution, metabolism, or excretion, or that may impair adherence to the study protocol;
• Those who have received any other study drug within 90 days before the first dose of the study drug;
• Those who have received other prescription or over-the-counter drugs that will effect the study evaluation considered by the investigator that within 14 days prior to the first administration of the study drug (or within 5 half-lives of the drug, whichever is longer）；
• Those who have donated blood or lost a lot of blood (\>400 ml) within 3 months before the first dose of the study drug;
• Major surgery or great trauma within 6 months before the first dose of the study drug (the investigator make the judgement based on the previous medical history);
• Consumption of beverages or foods containing grapefruit, pomegranate, papaya, grapes, carambola within 14 days, or do not agree to refrain from taking those beverages or foods every day during the study；
• Any alcoholic products within 48 hours before the first administration of the study drug, or disagree to refrain from taking any alcohol products every day during the study;
• Any foods or beverages rich in caffeine and xanthine within 48 hours before the first dose of the study drug(coffee, tea, coke, chocolate, seafood, animal liver, etc.) or disagree to refrain from taking those foods and beverages every day during the study;
• Abnormal ECG during screening or baseline period, which is judged to be clinically significant by the investigator; Or QTcF \> 450 ms during screening or baseline period；
• History of heart disease, including a family history of sudden death caused by cardiac causes or QT interval prolongation syndrome;
• History of serious kidney disease (judged by the investigator);
• Difficulty in venous blood collection, or known to have a history of needle fainting and blood fainting for many times;
• Clinical or laboratory evidence shows that there is one of the following situations: hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), syphilis carrying / infection;
• Any history of food and drug allergy of clinical significance judged by the investigator;
• Any history of drug abuse or urine drug test (+) in the screening period within 1 year before the first administration of the study drug;

Sponsors & Collaborators

• Zhejiang Palo Alto Pharmaceuticals, Inc.: lead

Study Sites (1)

Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Location

Study Officials

• Xuebing Yan, MD

  The Affiliated Hospital of Xuzhou Medical University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 12, 2022
• First Posted: July 21, 2022
• Study Start: June 28, 2020
• Primary Completion: December 12, 2020
• Study Completion: December 12, 2020
• Last Updated: July 21, 2022

Record last verified: 2022-07

Locations

CN (1)